HOLON, Israel, April 25,
2024 /PRNewswire/
-- Compugen Ltd.
(NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer
immunotherapy company and a pioneer in computational target
discovery, today announced that it will present new
clinical data on COM701 (anti-PVRIG) in triple combination
with COM902 (anti-TIGIT) and pembrolizumab
in microsatellite stable colorectal cancer at the American
Society of Clinical Oncology (ASCO) annual meeting on
May31-June 4 2023, in Chicago, Illinois.
Poster Presentation
Details:
Title: Preliminary
antitumor activity of COM701 in combination with COM902 and
pembrolizumab in patients with MSS-CRC and liver
metastases
Abstract Number:
3597
Session Title:
Gastrointestinal Cancer - Colorectal and Anal
Lead Author: Dr.
Manish Sharma
Date: Saturday, June 1, 2024; 1:30PM-4:30PM CDT
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT
component is derived from Compugen's clinical stage anti-TIGIT
antibody, COM902, in Phase 3 development by AstraZeneca through a
license agreement for the development of bispecific and
multispecific antibodies. In addition, the Company's
therapeutic pipeline of early-stage immuno-oncology programs
consists of programs aiming to address various mechanisms of immune
resistance, of which the most advanced program, COM503, is in IND
enabling studies is licensed to Gilead. COM503 is a potential
first-in-class, high affinity antibody which blocks the interaction
between IL-18 binding protein and IL-18, thereby freeing natural
IL-18 in the tumor microenvironment to inhibit cancer growth.
Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne Naughton,
Ph.D.
Head of Investor Relations and Corporate
Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-new-clinical-data-showing-com701-triple-combination-preliminary-anti-tumor-activity-in-microsatellite-stable-colorectal-cancer-with-liver-metastases-at-asco-2024-302127186.html
SOURCE Compugen Ltd.